Despite Heightened Concerns Over Influenza, the Most Commercially Important Viral Infections for Drug Developers Remain HIV, Hepatitis C, and Hepatitis B
Posted on: Wednesday, 22 February 2006, 09:00 CST
WALTHAM, Mass., Feb. 22 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that HIV, hepatitis C, and hepatitis B are the most important viral infections for drug developers. According to a new Spectrum report entitled Emerging Antiviral Drug Targets, large patient populations, high medical need, and the potential for chronic treatment make these drug markets lucrative for the biopharmaceutical industry.
Among these three infectious diseases, HIV has yielded the highest number of viable drug targets and candidates, partly because of the high level of investment in HIV research and the availability of predictive in vitro models for drug testing.
"Hepatitis C drug development has been hampered by the lack of reliable cell culture systems and animal infection models, but several promising targets, including protease and polymerase, have yielded drug candidates that could potentially revolutionize the treatment of hepatitis C," says John Lebbos, therapeutic area director of infectious diseases at Decision Resources, Inc. "In contrast to HIV and hepatitis C, which have a more diverse array of approaches in advanced stages of development, hepatitis B virus drug development is relatively concentrated within nucleoside analogues."
About Spectrum from Decision Resources
Spectrum is an executive advisory service that identifies and analyzes key business and technology drivers of the pharmaceutical and biotechnology markets. Available only through Decision Resources, Spectrum is a mix of publications and telephone inquiry access to analysts that provides an "over the horizon" perspective on complex health care issues.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
First Call Analyst: FCMN Contact:
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Research and Markets: Opioid Antagonists Are the Most Prevalent Drug Class in Late-Stage Development for the Alcohol Dependence Pipeline Which Include Two Reformulations of Naltrexone
- Research and Markets: The Mexican Pharmaceutical Market, Valued at US$11.3 Billion in 2005 - The Outlook for Pharmaceuticals: Mexico
- Research and Markets: Successful Development of the Sepsis Pipeline Might Lead to the First New Drug, Takedas Tak-242, Reaching the Market in 2009
- Research and Markets: Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development
- Research and Markets: Phosphodiesterases: A Drug Target Family With Broad Therapeutic Impact
- Survey Uncovers Surprising Attitudes towards HIV Vaccine Research
- Research and Markets : Overview of New Drug Research and Development in China
- Research and Markets : Analysis of New Drugs for Melanoma Currently Under Development
- Research and Markets: High Levels of Investment in the Development of Innovative Cancer Drugs Should Prove Successful in the Ways Which Cancer is Treated
- Research and Markets: Molecular Biomarkers for Clinical Diagnostics and Drug Discovery and Development
 |
 |
User Comments (0)
RSS Feeds